Compare Stocks → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BVXVNASDAQ:ENTXNASDAQ:MBOTNASDAQ:OTLK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsENTXEntera Bio$2.02+1.0%$1.65$0.52▼$3.35$58.18M1.7206,748 shs12,816 shsMBOTMicrobot Medical$0.86+0.1%$1.16$0.86▼$4.37$12.44M1.64121,429 shs20,826 shsOTLKOutlook Therapeutics$8.33+1.7%$8.56$4.00▼$40.60$108.37M0.04524,114 shs23,533 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%-26.92%ENTXEntera Bio-3.38%-10.71%+29.03%+131.27%+194.12%MBOTMicrobot Medical-3.12%-3.01%-23.27%-32.03%-43.40%OTLKOutlook Therapeutics-0.12%-1.21%-5.65%-5.21%-62.08%Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AENTXEntera Bio1.6257 of 5 stars3.53.00.00.03.30.00.0MBOTMicrobot Medical2.0592 of 5 stars3.53.00.00.03.70.80.0OTLKOutlook Therapeutics2.0824 of 5 stars3.42.00.00.02.81.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVXVBiondVax PharmaceuticalsN/AN/AN/AN/AENTXEntera Bio3.00Buy$10.00395.05% UpsideMBOTMicrobot Medical3.00Buy$7.00710.09% UpsideOTLKOutlook Therapeutics2.88Moderate Buy$46.43457.32% UpsideCurrent Analyst RatingsLatest ENTX, MBOT, BVXV, and OTLK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024MBOTMicrobot MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.004/2/2024ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/27/2024OTLKOutlook TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.003/25/2024OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.002/16/2024OTLKOutlook TherapeuticsCapital One FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight2/15/2024OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$60.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/AENTXEntera Bio$130K447.51N/AN/A$0.36 per share5.61MBOTMicrobot MedicalN/AN/AN/AN/A$0.38 per shareN/AOTLKOutlook TherapeuticsN/AN/AN/AN/A($1.11) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/AENTXEntera Bio-$8.89M-$0.31N/AN/AN/AN/A-101.78%-83.90%5/3/2024 (Estimated)MBOTMicrobot Medical-$10.74M-$1.08N/A∞N/AN/A-164.13%-125.22%5/15/2024 (Estimated)OTLKOutlook Therapeutics-$58.98M-$4.00N/AN/AN/AN/A-3,741.39%-132.37%5/20/2024 (Estimated)Latest ENTX, MBOT, BVXV, and OTLK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023MBOTMicrobot Medical-$0.25-$0.26-$0.01-$0.26N/AN/A3/8/2024Q4 2023ENTXEntera Bio-$0.08-$0.07+$0.01-$0.07N/AN/A2/14/2024Q1 2024OTLKOutlook Therapeutics-$1.00-$0.80+$0.20-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVXVBiondVax PharmaceuticalsN/A4.124.12ENTXEntera BioN/A10.3210.32MBOTMicrobot MedicalN/A2.092.09OTLKOutlook TherapeuticsN/A0.440.44OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVXVBiondVax Pharmaceuticals11.83%ENTXEntera Bio14.11%MBOTMicrobot Medical16.30%OTLKOutlook Therapeutics11.20%Insider OwnershipCompanyInsider OwnershipBVXVBiondVax Pharmaceuticals6.03%ENTXEntera Bio8.90%MBOTMicrobot Medical10.64%OTLKOutlook Therapeutics5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionableENTXEntera Bio1728.80 million26.24 millionOptionableMBOTMicrobot Medical2114.40 million12.87 millionOptionableOTLKOutlook Therapeutics2413.01 million12.32 millionOptionableENTX, MBOT, BVXV, and OTLK HeadlinesSourceHeadlineMedia advisory - OECD Economic Outlook 2024oecd.org - April 26 at 6:16 AMBest's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to Positivefinance.yahoo.com - April 22 at 1:21 PMUSD/JPY Forecast: BoJ’s Rate Hike Talks and the Yen’s Outlookfxempire.com - April 22 at 1:21 PMWGA Releases New Housing Finance Outlookmarkets.businessinsider.com - April 22 at 1:21 PMOutlook Money’s Tushar Ghosh elevated to Publishing Directorpitchonnet.com - April 22 at 1:21 PMOutlook: How to set up breaks between your meetingsmsn.com - April 22 at 1:21 PMOutlook Therapeutics, Inc. (OTLK)finance.yahoo.com - April 21 at 8:02 PMWorld Economic Outlook: IMF revises GDP predictions for LATAM and the Carribbeaninvezz.com - April 18 at 6:25 PMWorld Polyethylene High Density (HDPE) Market Outlook 2024-2033: Capacities, Production, Consumption, Trade Statistics, and Pricesfinance.yahoo.com - April 18 at 6:25 PMEconomic Outlook 2024 in Springfieldconnectionnewspapers.com - April 18 at 6:25 PMBosch Flags Further Cost Cuts After Giving 'Subdued' Outlook for 2024usnews.com - April 18 at 6:25 PMReporter's Guarentee | Outlook's Rakhi Bose In Conversation With Dalit Villagers In Saharanpur Districtoutlookindia.com - April 18 at 6:25 PMOutlook Therapeutics® Announces Closing of Private Placement of $5.0 Millionglobenewswire.com - April 15 at 4:15 PMBiotech on a Budget: 7 Stocks Under $10 With Huge Potentialinvestorplace.com - April 15 at 12:54 PMUS Consumer Sentiment Falls Slightly as Outlook for Inflation Worsensmsn.com - April 14 at 9:03 AMMicrosoft Outlook 2010's Default Profile Pic Was Based on Bill Gates' 1977 Mug Shot?msn.com - April 14 at 9:03 AMFed's Williams: Outlook is uncertain, Fed must be data-dependentfxstreet.com - April 11 at 6:05 PMNational Gas’ Summer Outlook 2024: Stable supply, reduced exportsenergylivenews.com - April 11 at 6:05 PMADB Outlook forecasts 7 % GDP growth in 2025bbs.bt - April 11 at 6:05 PMNatural Gas Price Forecast: Moving Average Breakout Improves Bullish Outlookfxempire.com - April 11 at 1:44 AMStock Market Today: Wall Street Falls After Hot Inflation Data Burns Hopes for a June Rate Cutmsn.com - April 11 at 1:44 AMBitdefender now has identity protection for Gmail and Outlookmsn.com - April 11 at 1:44 AMInsiders are Piling into These 10 Healthcare Stocks in 2024finance.yahoo.com - April 10 at 3:44 PMUsers Complain Gmail Blocks Email From Microsoft Outlook—Here’s The Fixforbes.com - April 3 at 3:14 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a monthApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a monthCaterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent3 Computer Vision Stocks for Long-Term Gains From AIApril 16, 2024 6:08 AMView 3 Computer Vision Stocks for Long-Term Gains From AIAll Headlines Company DescriptionsBiondVax PharmaceuticalsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Entera BioNASDAQ:ENTXEntera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Microbot MedicalNASDAQ:MBOTMicrobot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. In addition, it provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Outlook TherapeuticsNASDAQ:OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.